Cargando…
Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort
BACKGROUND: Aging in men is accompanied by a broad range of symptoms, including sexual dysfunction, cognitive and musculoskeletal decline, obesity, type 2 diabetes, cardiovascular disease and hypertension, organ degeneration/failure, and increasing neoplasia, some of which are associated with declin...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540576/ https://www.ncbi.nlm.nih.gov/pubmed/35770372 http://dx.doi.org/10.1111/andr.13220 |
_version_ | 1784803737913524224 |
---|---|
author | Anand‐Ivell, Ravinder Heng, Kee Severn, Katie Antonio, Leen Bartfai, Gyorgy Casanueva, Felipe F. Huhtaniemi, Ilpo T. Giwercman, Aleksander Maggi, Mario O'Neill, Terence W. Punab, Margus Rastrelli, Giulia Slowikowska‐Hilczer, Jolanta Tournoy, Jos Vanderschueren, Dirk Wu, Frederick C. W. Ivell, Richard |
author_facet | Anand‐Ivell, Ravinder Heng, Kee Severn, Katie Antonio, Leen Bartfai, Gyorgy Casanueva, Felipe F. Huhtaniemi, Ilpo T. Giwercman, Aleksander Maggi, Mario O'Neill, Terence W. Punab, Margus Rastrelli, Giulia Slowikowska‐Hilczer, Jolanta Tournoy, Jos Vanderschueren, Dirk Wu, Frederick C. W. Ivell, Richard |
author_sort | Anand‐Ivell, Ravinder |
collection | PubMed |
description | BACKGROUND: Aging in men is accompanied by a broad range of symptoms, including sexual dysfunction, cognitive and musculoskeletal decline, obesity, type 2 diabetes, cardiovascular disease and hypertension, organ degeneration/failure, and increasing neoplasia, some of which are associated with declining levels of Leydig cell‐produced testosterone. High natural biological variance, together with multiple factors that can modulate circulating testosterone concentration, may influence its interpretation and clinical implications. Insulin‐like peptide 3 is a biomarker of Leydig cell function that might provide complementary information on testicular health and its downstream outcomes. OBJECTIVES: To characterize insulin‐like peptide 3 as a biomarker to assess gonadal status in aging men. METHODS AND MATERIALS: A large European multicenter (European Male Aging Study) cohort of community‐dwelling men was analyzed to determine how insulin‐like peptide 3 relates to a range of hormonal, anthropometric, and lifestyle parameters. RESULTS AND DISCUSSION: Insulin‐like peptide 3 declines cross‐sectionally and longitudinally within individuals at approximately 15% per decade from age 40 years, unlike testosterone (1.9% per decade), which is partly compensated by increasing pituitary luteinizing hormone production. Importantly, lower insulin‐like peptide 3 in younger men appears to persist with aging. Multiple regression analysis shows that, unlike testosterone, insulin‐like peptide 3 is negatively dependent on luteinizing hormone and sex hormone‐binding globulin and positively dependent on follicle‐stimulating hormone, suggesting a different mechanism of gonadotropic regulation. Circulating insulin‐like peptide 3 is negatively associated with increased body mass index or waist circumference and with smoking, and unlike testosterone, it is not affected by weight loss in obese individuals. Geographic variation in mean insulin‐like peptide 3 within Europe appears to be largely explained by differences in these parameters. The results allowed the establishment of a European‐wide reference range for insulin‐like peptide 3 (95% confidence interval) adjusted for increasing age. CONCLUSION: Insulin‐like peptide 3 is a constitutive biomarker of Leydig cell functional capacity and is a robust, reliably measurable peptide not subject to gonadotropin‐dependent short‐term regulation and within‐individual variation in testosterone. |
format | Online Article Text |
id | pubmed-9540576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95405762022-10-14 Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort Anand‐Ivell, Ravinder Heng, Kee Severn, Katie Antonio, Leen Bartfai, Gyorgy Casanueva, Felipe F. Huhtaniemi, Ilpo T. Giwercman, Aleksander Maggi, Mario O'Neill, Terence W. Punab, Margus Rastrelli, Giulia Slowikowska‐Hilczer, Jolanta Tournoy, Jos Vanderschueren, Dirk Wu, Frederick C. W. Ivell, Richard Andrology Original Articles BACKGROUND: Aging in men is accompanied by a broad range of symptoms, including sexual dysfunction, cognitive and musculoskeletal decline, obesity, type 2 diabetes, cardiovascular disease and hypertension, organ degeneration/failure, and increasing neoplasia, some of which are associated with declining levels of Leydig cell‐produced testosterone. High natural biological variance, together with multiple factors that can modulate circulating testosterone concentration, may influence its interpretation and clinical implications. Insulin‐like peptide 3 is a biomarker of Leydig cell function that might provide complementary information on testicular health and its downstream outcomes. OBJECTIVES: To characterize insulin‐like peptide 3 as a biomarker to assess gonadal status in aging men. METHODS AND MATERIALS: A large European multicenter (European Male Aging Study) cohort of community‐dwelling men was analyzed to determine how insulin‐like peptide 3 relates to a range of hormonal, anthropometric, and lifestyle parameters. RESULTS AND DISCUSSION: Insulin‐like peptide 3 declines cross‐sectionally and longitudinally within individuals at approximately 15% per decade from age 40 years, unlike testosterone (1.9% per decade), which is partly compensated by increasing pituitary luteinizing hormone production. Importantly, lower insulin‐like peptide 3 in younger men appears to persist with aging. Multiple regression analysis shows that, unlike testosterone, insulin‐like peptide 3 is negatively dependent on luteinizing hormone and sex hormone‐binding globulin and positively dependent on follicle‐stimulating hormone, suggesting a different mechanism of gonadotropic regulation. Circulating insulin‐like peptide 3 is negatively associated with increased body mass index or waist circumference and with smoking, and unlike testosterone, it is not affected by weight loss in obese individuals. Geographic variation in mean insulin‐like peptide 3 within Europe appears to be largely explained by differences in these parameters. The results allowed the establishment of a European‐wide reference range for insulin‐like peptide 3 (95% confidence interval) adjusted for increasing age. CONCLUSION: Insulin‐like peptide 3 is a constitutive biomarker of Leydig cell functional capacity and is a robust, reliably measurable peptide not subject to gonadotropin‐dependent short‐term regulation and within‐individual variation in testosterone. John Wiley and Sons Inc. 2022-07-11 2022-10 /pmc/articles/PMC9540576/ /pubmed/35770372 http://dx.doi.org/10.1111/andr.13220 Text en © 2022 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Anand‐Ivell, Ravinder Heng, Kee Severn, Katie Antonio, Leen Bartfai, Gyorgy Casanueva, Felipe F. Huhtaniemi, Ilpo T. Giwercman, Aleksander Maggi, Mario O'Neill, Terence W. Punab, Margus Rastrelli, Giulia Slowikowska‐Hilczer, Jolanta Tournoy, Jos Vanderschueren, Dirk Wu, Frederick C. W. Ivell, Richard Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort |
title | Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort |
title_full | Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort |
title_fullStr | Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort |
title_full_unstemmed | Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort |
title_short | Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort |
title_sort | association of age, hormonal, and lifestyle factors with the leydig cell biomarker insl3 in aging men from the european male aging study cohort |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540576/ https://www.ncbi.nlm.nih.gov/pubmed/35770372 http://dx.doi.org/10.1111/andr.13220 |
work_keys_str_mv | AT anandivellravinder associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT hengkee associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT severnkatie associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT antonioleen associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT bartfaigyorgy associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT casanuevafelipef associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT huhtaniemiilpot associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT giwercmanaleksander associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT maggimario associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT oneillterencew associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT punabmargus associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT rastrelligiulia associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT slowikowskahilczerjolanta associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT tournoyjos associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT vanderschuerendirk associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT wufrederickcw associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort AT ivellrichard associationofagehormonalandlifestylefactorswiththeleydigcellbiomarkerinsl3inagingmenfromtheeuropeanmaleagingstudycohort |